Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31813608 | 1.00 | ERN1 (0.43) | ERN1ALDH1A1TSHRKRASTUBB1 | |
| SCHEMBL29956299 | 0.86 | KRAS (0.37) | ERN1ALDH1A1TSHRKRAS | |
| SCHEMBL1478144 | 0.86 | KRAS (0.37) | ERN1ALDH1A1TSHRKRAS | |
| SCHEMBL4540717 | 0.85 | ERN1 (0.43) | ERN1ALDH1A1TSHRKRASTUBB1 | |
| SCHEMBL1001988 | 0.84 | ERN1 (0.48) | ERN1ALDH1A1TSHRNFE2L2ABCG2 | |
| SCHEMBL29459689 | 0.84 | ERN1 (0.48) | ERN1ALDH1A1TSHRNFE2L2ABCG2 | |
| SCHEMBL953686 | 0.82 | ERN1 (0.44) | ERN1ALDH1A1TSHRKRASTUBB1 | |
| SCHEMBL14293093 | 0.81 | KRAS (0.35) | ERN1ALDH1A1KRAS | |
| SCHEMBL29712219 | 0.79 | ERN1 (0.46) | ERN1ALDH1A1KRASTUBB1 | |
| SCHEMBL26112209 | 0.79 | CA1 (0.49) | ERN1ALDH1A1KRASTUBB1AOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725942-A1 | COMPOUNDS ACTIVE ON CYCLIN D1 PATHWAY AND THEIR USE | Sibylla Biotech S.p.A. (IT) | 2026-04-15 | — | — | EP | disclosed |
| WO-2025124544-A1 | 3,4-DIHYDRO-2H-BENZO[B][1,4]DIOXEPANE COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 华润医药研究院（深圳）有限公司 | 2025-06-19 | — | — | WO | disclosed |
| EP-3625227-B1 | BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-14 | — | — | EP | disclosed |
| US-20220184236-A1 | NANOPARTICLE, CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING COMPRISING SAME AND ZWITTERIONIC LIGAND COMPOUND | National Institutes for Quantum Science and Technology (JP) | 2022-06-16 | — | — | US | disclosed |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-05-10 | — | — | US | disclosed |
| US-20220089455-A1 | METHOD FOR PRODUCING NANOPARTICLE HAVING METAL PARTICLE WHICH CONTAINS IRON OXIDE TO WHICH ONE OR MORE HYDROPHILIC LIGANDS ARE COORDINATION BONDED | ASTELLAS PHARMA INC. (JP) | 2022-03-24 | — | — | US | disclosed |
| EP-3904331-A1 | NANOPARTICLE, CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING COMPRISING SAME AND ZWITTERIONIC LIGAND COMPOUND | Astellas Pharma Inc. (JP) | 2021-11-03 | — | — | EP | disclosed |
| EP-3904294-A1 | METHOD FOR PRODUCING NANOPARTICLES INCLUDING METAL PARTICLES CONTAINING IRON OXIDE HAVING AT LEAST ONE HYDROPHILIC LIGAND COORDINATED THERETO | Astellas Pharma Inc. (JP) | 2021-11-03 | — | — | EP | disclosed |
| EP-3251678-B1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | ANACOR PHARMACEUTICALS INC (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3251678-B1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | ANACOR PHARMACEUTICALS INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-6894177-B2 | Intermediate compounds of non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2005-05-17 | — | — | US | disclosed |
| CN-1494545-A | Non-nucleoside reverse transcriptase inhibitors | ά | 2004-05-05 | — | — | CN | disclosed |
| US-6716850-B2 | ESPECIALLY N-(NITROGEN HETEROAR-2-YL)-SUBSTITUTED TETRAHYDROCYCLOPROPA(C)CHROMEN-1-UREAS AND THIOUREAS; TREATING HIV-1, PARTICULARLY A DRUG ESCAPE MUTANT. | MEDIVIR AB (SE) | 2004-04-06 | — | — | US | disclosed |
| CN-1143843-C | Process for preparing trifluoromethyl sulfoacid 2-trimethylammonium-4,5-dimethoxy-benzaldehyde | 中国科学院上海原子核研究所 | 2004-03-31 | — | — | CN | disclosed |
| WO-2004021969-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2004-03-18 | — | — | WO | disclosed |
| EP-1373261-A2 | CYCLOPROPAHETEROCYCLES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| US-20030187266-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| US-20030069224-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2003-04-10 | — | — | US | disclosed |
| WO-2002070516-A2 | CYCLOPROPAHETEROCYCLES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2002-09-12 | — | — | WO | disclosed |
| CN-1345720-A | Process for preparing trifluoromethyl sulfoacid 2-trimethylammonium-4,5-dimethoxy-benzaldehyde | SHANGHAI INST OF ATOMIC NUCLEU (CN) | 2002-04-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089455-A1 | METHOD FOR PRODUCING NANOPARTICLE HAVING METAL PARTICLE WHICH CONTAINS IRON OXIDE TO WHICH ONE OR MORE HYDROPHILIC LIGANDS ARE COORDINATION BONDED | FTH1, HAMP, TFRC | ERN1 4166/4885ALDH1A1 2870/4885TSHR 1072/4885 |
| US-20030069224-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, NAT10, NSUN2 | ERN1 175/4885ALDH1A1 1540/4885TSHR 2394/4885 |
| US-20030187266-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, NAT10, NSUN2 | ERN1 175/4885ALDH1A1 1540/4885TSHR 2394/4885 |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | PTGER4, PTGER1, PTGER2 | ERN1 1627/4885ALDH1A1 477/4885TSHR 704/4885 |
| US-20220184236-A1 | NANOPARTICLE, CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING COMPRISING SAME AND ZWITTERIONIC LIGAND COMPOUND | CD47, LPAR3, NMRAL1 | ERN1 3080/4885ALDH1A1 3785/4885TSHR 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.